[PDF] Top 20 Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer: US Oncologist Survey
Has 10000 "Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer: US Oncologist Survey" found on our website. Below are the top 20 most common "Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer: US Oncologist Survey".
Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer: US Oncologist Survey
... on ER/PR Positive HER2neu Negative Metastatic Breast Cancer for their open responses on clinical decisions, distributed and collected December 15, 2010 and January 10, ... See full document
5
More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review
... with Her2/neu-positive metastatic breast cancer, and to investigate the associations between different treatments and ...included: ER-positive or ... See full document
7
Prognostic Implications of ER, PR and HER2/Neu Protein Expression in a Cohort of Breast Carcinoma
... Abstract: ER, PR and HER 2/neu receptor studies are known to be prognostic and predictive biomarkers of breast ...of ER, PR and HER 2/neu receptors are routinely assessed ... See full document
6
Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis
... Results: A total of 11 studies, including 4,178 patients in the network meta-analysis, were included and analyzed. In terms of the pooled hazard ratios (HRs) for PFS, palbociclib plus fulvestrant was superior to other ... See full document
12
CD8+ tumor infiltrating lymphocytes strongly correlate with molecular subtype and clinico-pathological characteristics in breast cancer patients from Sudan
... Breast cancer treatment seems to have improved out- comes in most patients particularly with the advent of targeted therapy, however, a certain number of patients in Europe and North America still succumb ... See full document
6
Molecular subtyping of DCIS : heterogeneity of breast cancer reflected in pre invasive disease
... normal breast tissue were also included in the array as ...the ER status reported on a full section by the St Bartholomew’s histopathologist was recorded in order to compare with the scores from the ... See full document
9
Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)
... symptomatic breast cancer at presentation ...recurrent breast cancer, confirming that biopsy may be necessary to confirm disease recurrence in up to 10% of patients ...of ... See full document
9
/ISSN:1936-2625/IJCEP0001032 Case Report Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype
... that HER2- overexpressing and basal-like breast cancers are mutually exclusive ...that HER2 gene-amplifica- tion can take place also in a basal-like molecu- lar background to generate ... See full document
7
Critical analysis of the potential for targeting STAT3 in human malignancy
... approved cancer therapies target tyrosine kinases that are upstream of STAT3 activation, among other ...cell cancer cell lines with mutations in select tyrosine kinases do not exhibit decreased STAT3 ... See full document
12
Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer
... However, there are still limited conclusive data on whether bevacizumab plus hormone therapy as continuation therapy is superior to bevacizumab alone after stopping taxane-based therapy. In this retrospective analysis, ... See full document
7
<p>Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2− Advanced Breast Cancer</p>
... breast cancer. 28 In addition, related preclinical studies have shown that HER2+ breast cancer cell lines remain sensitive to CDKi, indicating that HER2+ breast ... See full document
10
A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
... receptor-positive metastatic breast cancer (MBC) patients progressed during or after prior endocrine ...3,910-hour positive MBC patients progressed on prior endocrine therapy were ... See full document
10
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
... HR-positive HER2-negative breast cancer had progressed on prior endocrine therapy confirmed the generally favorable safety profile that was also observed when palbociclib was combined ... See full document
35
Role of trastuzumab in the management of HER2-positive metastatic breast cancer
... Patients enrolled were included in two cohorts according to whether or not they had been previously exposed to trastu- zumab. Patients in the latter cohort had to have progressed after at least 6 weeks of trastuzumab ... See full document
17
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
... (HR+) metastatic breast cancer consists of a clinically heterogeneous group of tumors with different prognoses and responses to endocrine and ... See full document
28
Clinical utility of serum HER2/neu in monitoring and prediction of progression free survival in metastatic breast cancer patients treated with trastuzumab based therapies
... that HER2/neu gene ampli- fication, measured using FISH, is the best predictive marker of response to trastuzumab-based therapy ...culating HER2/neu ECD as a predictive marker of response to ... See full document
8
Potential of antibody–drug conjugates and novel therapeutics in breast cancer management
... of cancer over the past decade has been ...in HER2-positive patients has been proven to provide significant overall survival benefit in both metastatic and adjuvant ...both HER2 and ... See full document
10
Environmental radon exposure and breast cancer risk in the Nurses’ Health Study II
... lung cancer, demon- strating expected positive associations, and may be con- sidered a reasonable proxy of residential radon exposure ...with ER- breast cancer in Denmark ... See full document
14
Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium.
... Dutch Cancer Society [grants NKI 2007-3839; 2009 4363]; BBMRI-NL, which is a Research Infrastructure financed by the Dutch government (NWO ...Finnish Cancer Society, The Nordic Cancer Union and the ... See full document
15
Negative genic switch of HER 2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2 positive breast cancer
... by breast tissue micro- array (TMA) and matched node TMA that biomarkers’ status of metastatic nodal lesions could be a more accur- ate measurement for guiding adjuvant ... See full document
5
Related subjects